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Objectives To compare the performance and acceptability of unsupervised self-sampling with
clinician sampling for high-risk human papillomavirus (HPV) types for the ﬁrst time in a UK screening
setting.
Setting Nine hundred and twenty women, from two demographically different centres, attending for
routine cervical smear testing
Methods Women performed an unsupervised HPV self-test. Immediately afterwards, a doctor or
nurse took an HPV test and cervical smear. Women with an abnormality on any test were offered
colposcopy.
Results Twenty-one high-grade and 39 low-grade cervical intraepithelial neoplasias (CINs) were
detected. The sensitivity for high-grade disease (CIN2þ) for the self HPV test was 81% (95%
conﬁdence interval [CI] 60–92), clinician HPV test 100% (95% CI 85–100), cytology 81% (95% CI
60–92). The sensitivity of both HPV tests to detect high- and low-grade cervical neoplasia was much
higher than that of cytology (self-test 77% [95%CI 65–86], clinician test 80% [95% CI 68–88],
cytology 48% [95% CI 36–61]). For both high-grade alone, and high and low grades together, the
speciﬁcity was signiﬁcantly higher for cytology (greater than 95%) than either HPV test (between 82%
and 87%). The self-test proved highly acceptable to women and they reported that the instructions were
easy to understand irrespective of educational level.
Conclusions Our results suggest that it would be reasonable to offer HPV self-testing to women who
are reluctant to attend for cervical smears. This approach should now be directly evaluated among
women who have been non-attenders in a cervical screening programme.
INTRODUCTION
T
he National Health Service Cervical Screening
Programme has stated that its target is to ensure that
80% of eligible women are screened. Although,
overall, this target is being reached, it is recognized that
uptake is not consistent throughout the population. In
particular, women in inner city areas and from certain
ethnic groups are not attending at high levels.
1 Among the
reasons cited for the refusal to accept smear tests is the
nature of the gynaecological examination itself, which may
be embarrassing and culturally unacceptable to some
women.
2,3 Speciﬁc concerns are that male staff may be
present and that the examination will be painful. These
issues need to be addressed if uptake of screening is to be
improved. In this study, we aimed to assess whether women
ﬁnd screening more acceptable if women collected their
own sample instead of a speculum examination carried out
by a health-care professional.
To date, studies on human papillomavirus (HPV) self-
sampling have been carried out mostly in women with
abnormal smears, and a variety of sampling instruments
have been used.
4–38 Most importantly, in the majority of
studies, the women have taken their samples either under
the direct supervision of a health worker, or with verbal
instructions given at the time of the sampling. Such studies,
therefore, cannot be taken to be representative of the
envisaged scenario, in which women would be sent a
sampling kit and asked to perform the test in their own
home, without supervision. It is not known whether
samples taken under such circumstances would be of
comparable quality to those taken under supervision; this
study attempts to approximate as closely as possible the
scenario of self-testing in the home setting.
Most studies have focused thus far on the effectiveness of
the self-test to detect the presence or absence of HPV. Few
have incorporated measures of the acceptability of the test
or assessed attitudes toward self-testing among the women
to whom it is given. It has been found that not only do
women have genuinely negative experiences either during
the smear test or on receipt of their result,
39–41 but there is a
general lack of awareness of the link between cervical
cancer and HPV.
42,43 These studies have not asked women
directly whether they ﬁnd the test acceptable. This is
because there has, up until now, been no alternative to
which it can be compared. In the study described here,
women were asked to perform a self-test as well as having a
health professional carry out the test, and the acceptability
of the two methods was compared. The women’s stated
intention to use the self-test in the future provides an
indication of acceptability.
The objectives of this study were to compare the
performance of self-sampling with physician sampling
for high-risk HPV types, and to assess the acceptability of
self-sampling for HPV for the ﬁrst time in a UK screening
setting.
34
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This prospective study was carried out between January
2001 and November 2004 at two investigating centres, the
Margaret Pyke Centre, which is a large family planning
clinic in central London, and Hounslow Primary Care Trust,
in West London. Women who were due for a routine
screening smear and who had not previously had ablative or
excisional treatment of the cervix were eligible, and were
either identiﬁed opportunistically (at the Margaret Pyke
Centre) or from participating Feltham General Practitioners’
(GPs) Prior Notiﬁcation Lists (PNLs). In Feltham, all women
listed in the PNLs of participating GPs were informed of the
study and invited to contact the investigators if they were
interested in attending a research smear clinic held on a
particular day each week at a local clinic. The investigators
were contacted by 11.5% and 99.2% of these consented to
take part in the study. Women at the Margaret Pyke Centre
were approached opportunistically in the waiting room, and
it is not possible to say what proportion of these agreed to
participate. All women received a patient information sheet
explaining the study and provided written consent. Ap-
provals were obtained from the Local Research Ethics
Committees in Camden and Hounslow.
Before any tests, women were asked to complete a
questionnaire which collected demographic and psycho-
social information.
44 As described in detail below, the
women were then given the self-sampling HPV test kits,
followed by samples taken by a doctor or nurse for the
cervical smear test and clinician HPV test.
The women were also asked to ﬁll in a questionnaire
immediately after testing. This included speciﬁc questions
regarding the procedural acceptability of the HPV test that
the doctor/nurse performed and the HPV self-test. Women
were asked which of the two methods they found more
acceptable as well as questions about the self-test instruc-
tions and intentions to use the test in future.
A third questionnaire was posted to participants one week
after they had received the results of their smear and HPV
tests. This was designed to investigate the psychological
impact of both the smear result and the HPVresult. Results of
this aspect of the study have been published elsewhere.
42,45
Diagnostic tests
Women were provided with written instructions detailing
how to carry out the self-sampling test. They were advised
that the doctor or nurse could not help them or answer
questions relating to the performance of the self-test. This
ensured that the woman only had access to the same
resources as at home, i.e. written information and not an
expert. She was then left alone to carry out the procedure.
Following the self-test, a cervical smear and a clinician
HPV test were taken on the same visit by the doctor or
nurse. The sampling order was always therefore:
(1) Self-sampling HPV test using a cotton swab (Digene
kit);
(2) Cervical smear test for cytology using a pointed spatula
and endocervical brush;
(3) Clinician HPV test using the Digene Cervical Sampler
brush as provided in the Digene Hybrid capture II
(HCII) specimen transport medium kit (this HPV test
was taken with the speculum in situ).
The threshold for a positive cytology result is presented by
referral practice, i.e. referral for colposcopy is recommended
after a smear showing mild dyskaryosis or worse.
46 In
general, since HPV test positivity is not graded, a positive
HPV test is used as a criterion for colposcopy referral. Results
are then presented for high-grade disease alone, and for all
grades of disease.
HPV testing was carried out using the Digene HCII test for
both clinician and self-samples. Results were recorded in
relative light units (RLU) compared with a 1.0pg/mL
standard. A positive HPV result was deﬁned as a value
greater or equal to the standard threshold of 1.0pg/mL. Staff
in the cytology, histopathology and molecular biology
laboratories were blinded to other results.
If cytology results, on the same day as the HPV tests, were
unsatisfactory, results were used from the repeat cytology
where available. Median time for repeat cytology was 78
days (interquartile range [IQR] 69–108). The 12 remaining
unsatisfactory cytology results were not included in esti-
mates of cytology accuracy.
Reference tests
Women with either an abnormal cervical smear or a positive
HPV test result were offered colposcopy, with biopsy as
appropriate as the reference test. In addition, a randomly
selected 5% sample of women who tested negative on all
three tests were asked to attend for colposcopy, to ascertain
whether any disease could be missed by all the tests. A
previous study has indicated that this is sufﬁcient veriﬁca-
tion to ascertain whether any disease was likely to have
been missed in the triple negative group.
47
Histopathology was carried out at the Imperial Cancer
Research Fund (Cancer Research UK) laboratory and
reported by two histopathologists. Where there was dis-
agreement, a decision was reached by consensus. All
colposcopies were carried out by the same colposcopist
(AS). Low-grade disease on histopathology was deﬁned as
cervical intraepithelial neoplasia (CIN) 1 or less (i.e.
including borderline and HPV changes). High-grade disease
was deﬁned as CIN 2 and CIN 3 (there were no cases of
adenocarcinoma in situ or invasive cancer).
Statistical analysis
Comparison of sensitivity and speciﬁcity between the self
HPV, clinician HPV and cytology tests used paired compar-
isons for women with and without disease. Two disease
levels were used: (i) high-grade disease, (ii) low- and high-
grade disease, as determined by reference tests. The 95%
conﬁdence intervals (CIs) were calculated using the Wilson
method for estimates of sensitivity, speciﬁcity, positive
predictive value (PPV), negative predicative value (NPV)
and for differences between paired test results for sensitivity
and speciﬁcity. The 95% CIs for comparisons of unpaired
proportions for sensitivity and speciﬁcity used the New-
combe method for unpaired samples (CIA 2.1.1, Trevor
Bryant). Comparisons of PPVand NPVs for the two tests and
CI were not calculated since, as Leisenring et al
48 have
pointed out, for a paired study design these outcomes are
correlated, so there is no simple method of estimation of
variance of test statistic. All other statistical analyses were
undertaken in STATA v9.0.
Univariate logistic regression was used to identify possible
risk factors potentially associated with positive self or
clinician HPV results. A multivariate logistic regression
model was ﬁtted to take into account potential confounding
factors. The risk factors age, centre, current smoker, contra-
ceptive method and age of leaving full-time education were
HPV testing by self-sampling 35
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checking that there was an approximately linear relation-
ship between age and estimates of log odds ratio. All other
variables were treated as categorical variables. Analysis was
done separately for each HPV test. Relationships are
expressed as odds ratios (ORs) and 95% CIs for each risk
factor, with signiﬁcance assessed by P values computed from
Wald statistics.
The Standards for Reporting of Diagnostic Accuracy
checklist for reporting of diagnostic test studies was
followed,
49 and we report relevant items from the Quality
Assessment of Diagnostic Accuracy Studies quality assess-
ment tool.
50
RESULTS
Of the 925 women who consented to participate in the
study, ﬁve withdrew before having all tests taken. Thus, 920
women had all three tests on the same day. The median
length of time between the screening tests and colposcopy
was 63 days (IQR 49–84, range 1–276); it is unlikely that any
abnormalities would alter in that time. The median length of
time from date of screening test to receipt of cytology result
was 38 days (IQR 28–49, range 9–147), while the median
length of time from receipt of cytology result to colposcopy
was 26 days (IQR 14–35, range 49 to 226). Figure 1 (ﬂow
chart) shows the study recruitment.
Women in the two centres differed considerably in terms
of age of leaving full-time education and contraceptive use
(Table 1). The majority at Feltham had left education at or
before the age of 16 years, and were much less likely to be
using hormonal contraception. There were also differences
between the two centres in the percentage of women testing
positive for HPV with both tests (10% positive with the
clinician HPV test in Feltham versus 20% at Margaret Pyke).
Figure 2 shows the age distribution of women by HPV test in
1 6 participants with unsatisfactory smear + negative HPV tests had repeat smear only (no colposcopy)
Margaret Pyke Centre
Women attending clinic for
cervical smear test (n=672)
Feltham
Women identified from PNLs
                     
interested in participating and
contacted CRUK (n=253)
Consented (n=925)
• HPV self test
• Cytology 
• Clinician HPV test
Discharge to
routine screening  
(n=598)
5% random
sample invited to
attend colposcopy
(n=33)
Colposcopy (and repeat smear
if previous smear
unsatisfactory)
Biopsy Return to local management
Returned to
local
management
Referred for
treatment
Abnormal colposcopy (n=80) Normal colposcopy (n=199)
High grade histology
(n=21)
Low grade (n=39) and normal
(n=20) histology
All tests
negative Any abnormal test (n=238) or unsatisfactory
smear + negative HPV tests (n=45 + 61)
Withdrawn (n=5)
Withdrawn (n=37)
Figure 1 Study ﬂowchart. (
1Six participants with unsatisfactory smear þ negative HPV tests had repeat
smear only [no colposcopy])
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younger: the median age of 29 years compared with 41
years at Feltham. A higher proportion of younger women
have positive HPV results (Figure 2) similar to ﬁndings in
other studies.
47 This difference in age distributions between
the two centres explains the different percentages of women
testing positive for HPV (Figure 2).
Figure 3 shows a scatterplot of HPV values from the
self and clinician tests for each woman. The test threshold
for positive test results is indicated by dotted lines. The
test results are symmetrically distributed around the line
of agreement for women with at least one positive
result, suggesting that overall neither test gives consistently
higher values. Of the women with a positive HPV result,
52% (112/214) had higher values on the self-test, while
Table1 Characteristics and test results of participants by centre
Feltham Margaret Pyke Total
%( n)% ( n)% ( n)
Age left full time education
16 years or under 58 (145) 7 (47) 21 (192)
17–18 years 15 (36) 13 (85) 13 (121)
19 years or over 25 (62) 73 (494) 60 (556)
Missing data 2 (5) 7 (46) 6 (51)
Current smokers 23 (57) 28 (187) 27 (244)
Missing data 0 (0) 4 (25) 3 (25)
Contraceptive use
COC (Combined oral contraceptive pill) 13 (32) 51 (342) 41 (374)
Progestogen 7 (17) 17 (112) 14 (129)
Other* 80 (199) 30 (204) 44 (403)
Unknown 0 (0) 2 (14) 1 (14)
High-grade disease 1 (2) 3 (19) 2 (21)
Low-grade disease 2 (4) 5 (35) 4 (39)
Self HPV test positive 10 (24) 23 (153) 19 (177)
Clinician HPV test positive 10 (24) 20 (136) 17 (160)
Cytology (mild dyskaryosis and above) 4 (10) 6 (41) 6 (51)
Total 100 (248) 100 (672) 100 (920)
*All barrier and other methods grouped
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Figure 2 Age distribution of women by HPV result and centre. The
age distribution of women by clinician HPV test result: positive HPV
test results (black), negative HPV test (grey) for each centre, (A)
Feltham (B) Margaret Pyke
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Figure 3 Scatterplot of self and clinician HPV values. HPV test
values are shown for 918 women according to self and clinician HPV
tests conducted on the same day: D, women with high-grade disease;
m, women with low-grade disease; X, women without disease; -----,
corresponds to the standard threshold value (1.0pg/mL) for a positive
HPV test result, and values on or above this line correspond to positive
HPV test results; —, corresponds to the line of agreement where
values for self and clinician HPV tests are equal
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From Figure 3, the standard threshold for positive HPV
results corresponding to 1.0pg/mL appears to be an arbitrary
value, and a threshold value of 2 or 3 would include a
similar number of women with disease.
Figure 4 shows a receiver operating characteristic (ROC)
plot of sensitivity and speciﬁcity at different threshold values
for self and clinician HPV tests for women with high-grade
disease. CIs are shown for test thresholds of 1, 4 and 10pg/
mL. The a priori test threshold for this study is 1pg/ml and
this graph is for exploratory purposes only, but it does
suggest that the sensitivity of the self-test falls off faster at
high thresholds than the clinician test. This difference arises
from the higher values for the clinician HPV test compared
with the self HPV test for women with high-grade disease, a
pattern not seen for the total group of 214 women with
positive HPV values (Figure 3). Choosing a different
threshold based on these data is likely to introduce bias,
which will overestimate values of sensitivity, particularly as
there are fewer than 50 women with high-grade disease.
51
Test adequacy
There were 61 unsatisfactory cytology smears while there
were no unsatisfactory HPV tests (two HPV samples were
lost). Thus, cytology has greater potential for requiring recall
of women for repeat testing, with all the inconvenience and
extra costs this entails.
Test accuracy for diagnosis of high-grade disease
Measures of test accuracy, sensitivity and speciﬁcity are
compared for their accuracy to diagnose high-grade disease
in all three diagnostic tests (Table 2). Sensitivity is compared
for the 21 disease positive women and speciﬁcity for the 899
women without high-grade disease. The self HPV test gave
high values for both sensitivity and speciﬁcity, although
these were below the values for the clinician test. There is
no statistically signiﬁcant difference between these sensitiv-
ity values (19% difference, 95% CI of  0.2–40), but the CI is
wide due to the low number of women with high-grade
disease in the study. There is a marginally signiﬁcant
difference between the speciﬁcity of the self and clinician
HPV tests (2% difference, 95% CI of 0.3–4). PPVs and NPVs
are similar between the self and clinician HPV tests. There is
no statistically signiﬁcant difference in the sensitivity
between cytology and either of the two HPV tests. The
speciﬁcity of cytology is signiﬁcantly higher than the
speciﬁcity of the self HPV test (14% higher, 95% CI of
12–17) and clinician HPV test (12%, 95% CI of 9–14). The
NPVs of cytology and the HPV tests are similar, but the PPV
of cytology is higher than the PPV for the HPV tests and the
CIs do not overlap.
Test accuracy for high- and low-gradedisease
Although the primary purpose of this study was to assess the
performance of the tests in women with high-grade disease,
in practice it is interesting to look at the real-life situation of
criteria which would lead to referral for colposcopy. It is
recommended that women should be referred for colpo-
scopy after a smear showing mild dyskaryosis or worse.
46
Since HPV tests are not graded, we assume referral for
colposcopy after a positive HPV test.
Of the 920 women participating in this study, 60 were
diagnosed with either low- or high-grade disease. Measures
of test accuracy were calculated for all three tests to identify
women with high- and low-grade disease (Table 3). The
sensitivity of both HPV tests to detect high- and low-grade
disease was much higher than that of cytology (self HPV test
29% higher, 95% CI 13–42; clinician HPV test 32% higher,
95% CI 16–45), whereas the speciﬁcity of cytology was
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Figure 4 Receiver operating characteristic (ROC) plot of self and
clinician HPV test thresholds for women with high-grade disease. ROC
plots showing sensitivity and speciﬁcity across different thresholds for
the self and clinician HPV tests. Sensitivity with its 95% CIs is shown
for threshold values corresponding to 1, 4 and 10pg/mL for self HPV
( ) and clinician HPV (’) tests
Table2 Performance of the tests in women with high-grade disease
% (95% CI) Self HPV test Clinician HPV test Cytology (mild dyskaryosis and above)*
Sensitivity 81% (17/21) 100% (21/21) 81% (17/21)
(60–92%) (85–100%) (60–92%)
Speciﬁcity 82% (739/899) 85% (760/899) 96% (853/887)
(80%–85%) (82–87%) (95–97%)
PPV 10% (17/177) 13% (21/160) 33% (17/51)
(6–15%) (9–19%) (22–47%)
NPV 99% (739/743) 100% (760/760) 99.5% (853/857)
(99–100%) (99–100%) (99–100%)
*12/899 women without high-grade disease had unsatisfactory cytology test results and were not included in calculations of estimates for cytology. There was no evidence of an association
between unsatisfactory cytology results and either of the HPV test results
38 Szarewski et al.
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HPV test 10% lower, 95% CI 8–13). Likewise, there was a
higher PPV for cytology compared with the HPV tests. The
NPVs appear very similar across all the tests.
There was no statistically signiﬁcant difference between
the sensitivity of the self and clinician HPV tests. There was a
small difference between the speciﬁcity of the self and
clinician HPV tests which was just statistically signiﬁcant
(2.2% difference, 95% CI of difference of 0.2–4.3) with self-
HPV having a lower speciﬁcity.
Comparisonoftest accuracyin different age groups
Figure 2 demonstrated the importance of age in the
frequency of HPV positivity. Table 4 shows that the
speciﬁcity of both HPV tests as a predictor of disease is
signiﬁcantly higher in women aged 30 years or above (7%
difference, 95% CI 3–12 for the clinician HPV test) while
maintaining similar sensitivity.
Colposcopyoftherandomized triple-negative
sample
Thirty-three women who tested negative on all three tests
were randomly selected to attend for colposcopy, but only
16 (48%) attended. One of these women was found to have
low-grade CIN on biopsy, while the rest of them had a
normal colposcopy. This is congruent with previous studies
that showed no signiﬁcant disease is missed by the
combination of cytology and HPV testing.
47
Risk factors for positive HPV test results
Table 5 shows the results from univariate and multivariate
logistic regression of risk factors for positive results with
each HPV test.
In univariate analyses, contraceptive method and educa-
tional level were associated with a positive HPV result for
both self-test and clinician test. Multivariate analysis
indicated that none of these variables were strong predictors
for a positive HPV result. Age was signiﬁcantly associated
with HPV positivity, with an OR decreasing by 6% per year
for each test (95% CI 4–8). The results for the self and
clinician HPV tests were broadly similar
Acceptability
The self-test proved highly acceptable to women at both
clinics, with 73% of women stating that they would prefer
to use the self-test at home rather than come to the clinic.
Despite the demographic differences between the two
populations, over 98% of women in both clinics reported
that the instructions were easy to understand. A full report
of the ﬁndings of the questionnaires on acceptability and
perceptions is given elsewhere.
52
DISCUSSION
This study is unique as it looks at both accuracy and
acceptability of unsupervised self-testing and clinician HPV
testing, compared with cytology, in a screening population
in the UK.
We found no signiﬁcant difference in sensitivity between
the clinician and self HPV tests for women with high-grade
disease, although the self HPV test missed four of the 21
women with high-grade disease and the clinician sample
missed none. However, the low number of women with
high-grade cervical neoplasia in this screening population
limits the conclusions that can be drawn from comparisons
of the sensitivity of these tests for high-grade disease. For
women with high- and low-grade disease, we found that the
sensitivity of the clinician and self HPV tests was rather
similar. There was a marginal difference in speciﬁcity of 2%
Table3 Performance of the tests in women with high- or low-grade disease
% (95% CI) Self HPV test Clinician HPV test Cytology (mild dyskaryosis and above)*
Sensitivity 77% (46/60) 80% (48/60) 48% (29/60)
(65–86%) (68–88%) (36–61%)
Speciﬁcity 85% (729/860) 87% (748/860) 97% (826/848)
(82–87%) (85–89%) (96–98%)
PPV 26% (46/177) 30% (48/160) 57% (29/51)
(20–33%) (23–38%) (43–70%)
NPV 98% (729/743) 98% (748/760) 96% (826/857)
(97–99%) (97–99%) (95–97%)
*12/861 women without high- or low-grade disease had unsatisfactory cytology results
Table4 Comparison of sensitivity and speciﬁcity of HPV tests in younger and older age groups (both high- and low-grade disease)
Age groups % (n/N) (95% CI) Self HPV sensitivity Clinician HPV sensitivity Self HPV speciﬁcity Clinician HPV speciﬁcity
20–29years 76% (32/42) 81% (34/42) 80% (270/339) 83% (280/339)
(62–87%) (67–90%) (75–84%) (78–86%)
30 years plus 78% (14/18) 78% (14/18) 88% (459/521) 90% (468/521)
(53–90%) (59–94%) (85–91%) (87–92%)
Difference between age groups* 2%  3% 8% 7%
( 21–24%) ( 28–16%) (4–14%) (3–12%)
*Unpaired proportions
HPV testing by self-sampling 39
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favour of the clinician test. Both HPV tests were at least as
sensitive as cytology (equal for high grade, higher than
cytology for all grades), emphasizing that this is a viable
alternative when clinician-based cytology cannot be
obtained. However, speciﬁcity was signiﬁcantly lower for
both tests as compared with cytology. The NPVof either HPV
test is at least as good as that of cytology (X to 99% for all
tests). Cytology was unsatisfactory in 7% of women,
whereas there were no unsatisfactory HPV tests.
On average, the RLU values for both types of HPV test were
similar (Figure 3). HPV levels tended to be higher in the
clinician samples for the 21 women with high-grade disease
and, consequently, there is a higher sensitivity for the
clinician HPV test in this group. However, the importance
of this difference is unclear as no such difference in HPV
levels, between the clinician and self-tests, was seen either in
the 39 women with low-grade disease or the 154 women
who were HPV positive but without disease. The self HPV test
has slightly higher RLU values in women with negative HPV
results, but this is not clinically signiﬁcant and is over-
emphasized in Figure 3 due to the log scale. Interestingly,
some women had much higher values on the self-test than
on the clinician sample, which raises the possibility of
sampling having occurred from different genital areas.
There is no evidence that the women recruited through
the clinic in a less socio-economically advantaged area
(Feltham, Table 1) were less able to perform the self-test.
Although more women at the Margaret Pyke Centre had
positive HPV results, at each centre, a similar number of
women tested positive by both self and clinician tests. In
both centres, women found the instruction sheet easy to
understand and the self-test highly acceptable.
Although there was low uptake in Feltham, this is not
likely to have had an effect on the comparison of self and
clinician HPV test results, as both samples were from the
same woman. Though there were few women with disease,
both the CIN rates and the HPV positivity rates are
compatible with those of other screened populations.
47,53
Our results suggest that it would be reasonable to offer home
HPV self-testing to women who are reluctant to attend for
cervical smears. The sensitivity and NPVs of this test provide
evidence that they would not be disadvantaged compared
with women who attend for cytological screening. Other
studies from our group have suggested that self-sampling
would be acceptable to ethnic minority women.
54,55 This
approach should now be directly evaluated among women
who are non-attenders in the cervical screening programme.
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Table5 Logistic regression of factors leading to positive HPV test result
Risk factor
Self HPV test odds ratio (95% CI),
P value
Clinician HPV test odds ratio (95% CI),
P value
Logistic regression: univariate analysis (n¼920)
Age (per year) 0.94 (0.92–0.96), Po0.001 0.94 (0.92–0.96), Po0.001
Centre
Feltham 1 1
Margaret-Pyke 2.75 (1.74–4.35), Po0.001 2.37 (1.49–3.76), Po0.001
Current smoker
No 1 1
Yes 1.55 (1.09–2.21), P¼0.014 1.18 (0.81–1.72), P¼0.39
Contraceptive method Overall P¼0.005 Overall P¼0.02
Progestogen only 1 1
COC 1.78 (1.04–3.03) 1.25 (0.75–2.10)
Other 1.03 (0.60–1.78) 0.74 (0.44–1.27)
Age left education Overall P¼0.001 Overall P¼0.022
16 years or under 1 1
17 to 18 years 1.26 (0.64–2.49) 1.20 (0.62–2.35)
19 years or above 2.28 (1.40–3.72) 1.85 (1.14–3.00)
Logistic regression: multivariate analysis (n¼855)
Age per year (n¼855) 0.95 (0.93–0.98), Po0.001 0.95 (0.92–0.97), Po0.001
Centre
Feltham (n¼243) 1 1
Margaret-Pyke (n¼612) 1.67 (0.93–3.01), P¼0.09 1.62 (0.90–2.94), P¼0.11
Contraceptive method Overall P¼0.48 Overall P¼0.91
Progestogen only (n¼121 1 1
COC (n¼350) 1.38 (0.79–2.45) 0.92 (0.53–1.58)
Other (n¼384) 1.40 (0.78–2.52) 1.00 (0.56–1.76)
Current smoker
No (n¼621) 1 1
Yes (n¼234) 1.36 (0.78–1.99), P¼0.11 0.98 (0.66–1.46), P¼0.92
Age left education Overall P¼0.42 Overall P¼0.64
16 years or under (n¼192) 1 1
17 to 18 years (n¼119) 0.78 (0.38–1.66) 0.71 (0.34–1.48)
19 years or above (n¼544) 1.15 (0.63–2.11) 0.88 (0.48–1.62)
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general practices in Feltham which participated in the study,
and the women who volunteered at both centres. HPV
testing kits were provided by Digene Corporation.
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